乳腺磁共振成像(MRI)对近期诊断为纯导管原位癌(DCIS)患者检测额外病灶是否有用
单中心回顾性研究纳入108例纯DCIS患者,76例接受乳腺MRI分期,36%发现可疑额外病灶,23例(85%)行MRI引导活检,6例(26%)确诊额外癌灶(5例DCIS、1例浸润性导管癌),均位于对侧,占全部76例的7.9%(95%CI 3.7%–16.2%),其中1.3%(95%CI 0.2%–7%)为浸润性癌且生物标志物与原发灶不一致。
要点
- 76例纯DCIS中36%因MRI发现可疑额外病灶,其中23例(85%)行MRI引导活检,6例(26%)确诊额外癌灶,均位于对侧。
- 额外癌灶总体检出率7.9%(95%CI 3.7%–16.2%),浸润性额外癌灶占全部76例的1.3%(95%CI 0.2%–7%)。
- 1例对侧浸润性导管癌的ER/PR状态与原发纯DCIS不一致(原发ER/PR阴性,对侧IDC ER/PR阳性)。
核心结论
- 在76例近期诊断的纯DCIS并接受分期乳腺MRI的患者中,约8%(95%CI 3.7%–16.2%)诊断额外癌灶,1.3%(95%CI 0.2%–7%)的额外癌灶为浸润性且生物标志物不同,改变了治疗和预后。
研究设计与样本
- 单中心回顾性研究,2013年1月至2015年4月纳入108例纯DCIS患者,其中76例接受乳腺MRI分期;分析乳腺X线、超声和MRI影像及原发DCIS的病理和生物标志物特征,并描述MRI偶然发现的额外病灶。
关键影像表现/征象
- 76例中52例(68%)有可疑新发现(27例,36%)或肿瘤尺寸大于乳腺X线原显示(43例,57%)。
- 27例(36%)MRI发现可疑额外病灶,其中4例在同侧乳腺,23例在对侧乳腺。
- 6例(26%)经MRI引导活检确诊额外癌灶(5例DCIS、1例IDC),全部位于对侧乳腺,同侧无第二病灶。
- 额外病灶大小0.4–8 cm(平均3.1 cm),该组原发灶大小0.1–10.9 cm(平均5.6 cm),年龄44–63岁(中位52.5岁)。
- 6例中5例(83%)原发纯DCIS为ER/PR阳性,1例(17%)为ER/PR阴性;2例第二病灶无生物标志物数据,3例与原发灶一致,1例对侧IDC与原发纯DCIS不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine if breast MRI is useful for detecting additional or invasive sites of disease in patients initially diagnosed with pure DCIS.
MATERIALS AND METHODS: A retrospective review of women diagnosed with pure DCIS who underwent a breast MRI for evaluation of extent of disease was performed at a single institution from January 2013 to April 2015. Data analysis included imaging (mammography, ultrasound and MRI) and pathology characteristics (histology and biomarker status) of the primary DCIS as well as descriptors for the additional sites of disease incidentally found by breast MRI.
RESULTS: A total of 108 patients were diagnosed with pure DCIS during this time period. A breast MRI for staging was recommended for all patients. 76 patients had an MRI performed, ages ranging from 38 to 79 years old (median, 53 years); sizes ranging from 0.3 to 10cm (mean, 2.2cm). A total of 52 patients (68%) either had suspicious new finding(s) (n=27, 36%) or bigger tumor size than originally visualized on mammography (n=43, 57%). A total of twenty-seven patients (36%) had other MRI findings suspicious for additional sites of disease in either breast (four in the ipsilateral breast and twenty-three in the contralateral breast). From this group of patients, twenty-three (85%) patients underwent MRI-guided biopsy as recommended. The four patients who did not have the recommended MRI guided-biopsy either underwent total mastectomies or refused the biopsy. Six out of the twenty-three patients (26%) were diagnosed with an additional site of cancer (5 DCIS and 1 IDC) (7.9%, CI=3.7%, 16.2%). All of the six patients had contralateral disease (100%) and none had a second site of disease in the ipsilateral breast. The size of the additional sites of disease ranged from 0.4 to 8cm (mean, 3.1cm) and the size of the primary lesion in this selected group ranged from 0.1 to 10.9cm (mean, 5.6cm). Ages ranged from 44 to 63 years old (median, 52.5 years). Five out 6 patients (83%) presented with the first site of disease as pure DCIS with estrogen (ER) and progesterone (PR) receptors positive and one case (17%) was pure DCIS ER/PR- negative. The second incidental lesion found on MRI demonstrated 5 cases of contralateral pure DCIS and 1 case of contralateral invasive disease. From this group, we did not have the data for biomarker analysis for the second site of disease in 2 cases and 3 cases showed concordant biomarker status between the first and second sites of disease. The 1 case that presented with an invasive component in the contralateral side of the initially biopsy-proven pure DCIS had discordant biomarkers compared to the first site of disease: the first site of pure DCIS was ER/PR-negative and the second site of invasive ductal carcinoma (IDC) presented with ER/PR-positive status.
CONCLUSION: From a total of 76 patients with recent diagnosis of pure DCIS who underwent staging breast MRI examination for diagnosis of additional sites of disease, approximately 8% (95% confidence interval=3.7%, 16.2%) was diagnosed with an additional site of cancer and 1.3% (95% confidence interval=0.2%, 7%) of the total cases had invasive disease in the additional sites with different biomarker status; changing their management and prognosis.
引用
- Benveniste AP, Ortiz-Perez T, Ebuoma LO, et al. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)? Eur J Radiol. 2017. PMID: 29103479. doi:10.1016/j.ejrad.2017.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。